Call: 1-877-689-6082
Health News

The bioavailability of Coenzyme Q10 supplements available in New Zealand differs markedly with Q-Gel

An article in The New Zealand Medical Journal (October 8, 2004 Vol 117 No 1203) was entitled “The bioavailability of coenzyme Q10 supplements available in New Zealand differs markedly&rdquo..

Read more...

Featured Product

From the makers of one of the top selling calcium supplements in the health food industry.

Non-GMO!
Liquid Calcium with Magnesium™

90 Softgels $13.25
View more featured products...

News from Tishcon Corp.

News: Tishcon Corp. (the manufacturer of our Q-Gel CoQ10) has received an orphan drug designation for UbiQ-Gel® (CoQ-10) in the treatment of mitochondrial cytopathies. Phase 1 Clinical trials for UbiQ-Gel® have begun at the Children's Hospital Medical Center in Cincinnati, Ohio. UbiQ-Gel® is being clinically tested for use in the treatment of mitochondrial cytopathies a group of rare but debilitating diseases including MELAS syndrome, MERRF syndrome, and Kearnes-Sayre syndrome. All of which can cause heart disturbances, dementia, movement disorders, stroke-like episodes and seizures. All these diseases are thought to be caused by problems in the mitochondria, structures that produce energy in the body's cells. The heart contains the single largest concentration of CoQ10 in the body. And, CoQ10 has been clinically shown to improve heart function!


Comment







Captcha Image


Go back to Health News.